科研之友
微信
新浪微博
Facebook
分享链接
摘要
OBJECTIVE: To assess cardiovascular risks associated with supplemental calcium use to assist clinicians with evidence-based recommendations for patients who have, or who are at risk for, osteoporosis or osteopenia. %26lt;br%26gt;DATA SOURCES: Literature was accessed through December 2011 using MEDLINE, Cochrane Library, and International Pharmaceutical Abstracts using the terms calcium compounds and cardiovascular disease. In addition, reference citations from the publications identified were reviewed. %26lt;br%26gt;STUDY SELECTION AND DATA EXTRACTION: All English-language articles were evaluated. Randomized controlled trials, observational studies, and meta-analyses were included. %26lt;br%26gt;DATA SYNTHESIS: While supplemental calcium and vitamin D have been demonstrated to improve bone mineral density and decrease the risk of fractures, there have been recent reports that calcium supplements may increase the risk for cardiovascular events. Nine clinical trials and/or meta-analyses were reviewed; 3 documented increases in cardiovascular risk associated with calcium supplements, and 6 did not. No studies were designed to assess cardiovascular outcomes as primary end points. Balancing the evidence from these analyses with the results of randomized controlled trials assessing the effect of calcium on fracture prevention suggests that the benefits of calcium outweigh the cardiovascular risk. %26lt;br%26gt;CONCLUSIONS: At this time, there is no cause to change routine practice surrounding supplemental calcium use in patients who have, or are at risk for, osteoporosis or osteopenia.
- 出版日期2012-5
